| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Jul 2025 | 21 May 2025 |
| Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve the audited financial results of the Company for the quarter and year ended March 31 2025 Intimation regarding postponement of Board Meeting dated 30.05.2025 and reason for delay in submission of audited financial results The Board Meeting to be held on 30/05/2025 Stands Cancelled. Board Meeting proposed to be held on 30.05.2025. Accordingly, the said board meeting is being postponed and the revised date of the meeting will be intimated in due course. (As Per BSE Announcement Dated on 29.05.2025) Further, in continuation to our earlier intimations dated May 21, 2025, and May 29, 2025, and in accordance with the Trading Window Closure intimation dated March 29, 2025, the Trading Window for all designated persons as under Insider Trading Policy of the Company is closed from April 01, 2025 till July 21, 2025 (both days inclusive). Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2025 ,inter alia, to consider and approve the audited financial results of the Company for the half-year and the financial year ended March 31, 2025 and to take note of the auditors report thereon (As Per BSE Announcement Dated on :16.07.2025) Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2025 ,inter alia, to consider and approve the financial results of the Company for the period ended March 31, 2025 (As Per BSE Announcement Dated on: 19/07/2025) | ||
| Board Meeting | 6 May 2025 | 6 May 2025 |
| Outcome of Board Meeting held on 06.05.2025 - Preferential Allotment of Equity shares pursuant to conversion of unsecured loan into equity shares | ||
| Board Meeting | 6 Dec 2024 | 3 Dec 2024 |
| Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/12/2024 inter alia to consider and approve conversion of unsecured loans from Promoters and others into equity shares and increase in the authorized capital as per requirement Outcome of Board Meeting held on 06.12.2024 (As Per BSE Announcement dated on 06.12.2024) | ||
| Board Meeting | 14 Nov 2024 | 11 Nov 2024 |
| Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve un-audited financial statements of 30.09.2024 and to consider conversion of unsecured loans into equity shares Outcome of Board Meeting held on 14.11.2024 (As Per Bse Announcement Dated on 14.11.2024) | ||
| Board Meeting | 6 Sep 2024 | 6 Sep 2024 |
| Outcome of Board Meeting held on 06.09.2024 - Reappointment of Independent Directors, Secretarial & Internal Auditors and regarding 8th AGM of the Company | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.